Translational Clinical Oncology


Research in the field of clinical oncology aims to advance the treatment of cancer, with a particular focus on chemotherapy, but also supportive care. Translational clinical oncology is a field of study that aims to translate the findings arising from basic research (e.g. in the fields of pharmacology, pharmacogenetics or tumor biology) into clinical oncology practice.
The Department of Translational Clinical Oncology was founded in October 2003 to facilitate such translational research and to develop an effective database system to support the implementation of clinical trials.

Research and Education

(1) Clinical study of cancer chemotherapy: Using the originally developed clinical trial database system, we have conducted a number of phase II clinical trials such as TS-1 and docetaxel for the treatment of previously treated non-small cell lung cancer, and TS-1 and gemcitabine for the treatment of recurrent or inoperable biliary tract cancers. We have also conducted some outcomes studies, for example of modified FOLFOX6 for the treatment of advanced or recurrent colorectal cancer.
(2) Clinical study of supportive care in cancer chemotherapy: We are exploring measures to alleviate the pain associated with gemcitabine infusion, and investigating the risk factors for chemotherapy-induced anemia and oxaliplatin-induced allergic reactions.
(3) Pharmacogenetic study in cancer chemotherapy: We are investigating the relationships between genetic polymorphisms and the incidence of adverse events and/or the effectiveness of a treatment. We are currently studying pharmacogenetic factors in TS-1 treatment for gastrointestinal cancer and oxaliplatin-induced sensory neuropathy. We also investigate relation between genomic alterations in gastrointestinal cancers and prognostic or predictive factors in cancer chemotherapy.

Fig. 1. Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer: Kaplan–Meier survival curves demonstrating overall (solid line) and progression-free (dashed line) survival. OS overall survival, PFS progression-free survival

Recent Publications

(1) Yamamoto K, Matsumoto S, Tada H, Yanagihara K, Teramukai S, Takemura T, Fukushima M. A data capture system for outcomes studies that integrates with electronic health records: development and potential uses. J Med Syst. 2008;32:423-7.
(2) Yanagihara K, Yoshimura K, Niimi M, Yasuda H, Sasaki T, Nishimura T, Ishiguro H, Matsumoto S, Kitano T, Kanai M, Misawa A, Tada H, Teramukai S, Mio T, Fukushima M. Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer. Cancer Chemother Pharmacol. 2010 Jan 13. [Epub ahead of print]
(3) Kanai M, Yoshioka A, Tanaka S, Nagayama S, Matsumoto S, Nishimura T, Niimi M, Teramukai S, Takahashi R, Mori Y, Kitano T, Ishiguro H, Yanagihara K, Chiba T, Fukushima M, Matsuda F. Associations between glutathione S-transferase pi Ile(105)Val and glyoxylate aminotransferase Pro(11)Leu and Ile(340)Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiol. 2010 Mar 20. [Epub ahead of print]
(4) Matsumoto S, Nishimura T, Kanai M, Mori Y, Nagayama S, Kawamura J, Nomura A, Miyamoto S, Kitano T, Ishiguro H, Yanagihara K, Teramukai S, Sakai Y, Chiba T, Fukushima M. Safety and Efficacy of Modified FOLFOX6 for Treatment of Metastatic or Locally Advanced Colorectal Cancer: A Single-Institution Outcome Study. Chemotherapy 2008;54:395–403
(5) Kitano T, Tada H, Nishimura T, Teramukai S, Kanai M, Nishimura T, Misawa A, Yoshikawa K, Yasuda H, Ishiguro H, Matsumoto S, Yanagihara K, Fukushima M. Prevalence and incidence of anemia in Japanese cancer patients receiving outpatient chemotherapy. Int J Hematol. 2007;86:37-41.


Program-Specific Assistant Professors:Yukiko Mori, Takeshi Maeda, Tomomasa Hayashi
TEL : +81-75-751-4770
FAX : +81-75-751-4772
e-mail :